Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
French cancer focused biotech Transgene has appointed two seasoned leaders in oncology who will be instrumental in advancing the company’s innovative immunotherapy programs 10 September 2024
Italy-based biotech AAVantgarde Bio has appointed Jayashree Sahni as its new chief medical officer, replacing Naveed Shams, who has held the role since 2022. 10 September 2024
California’s Lykos Therapeutics is still trying to regroup after being rocked by the US Food and Drug Administration’s (FDA) rejection of midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD). 6 September 2024
Biosimilar-focused biopharmaceutical company and contract development and manufacturing organization (CDMO) Tanvex BioPharma has named Stephen Lam its new chief executive (CEO). 5 September 2024
Novocure (Nasdaq: NVCR) has announced that chief executive Asaf Danziger will retire at the end of 2024, with current chief financial officer Ashley Cordova set to succeed him as CEO. 4 September 2024
Privately-held German biotech firm Immatics Biotechnologies today announced that Harpreet Singh has been appointed the company’s chief executive (CEO). 8 July 2019
After the failure of its latest drug candidate in clinical trials, US oncology specialist Merrimack Pharmaceuticals has issued a document to the US Securities and Exchange Commission, announcing the departure of the company’s top two executives. 4 July 2019
French nanomedicine company Nanobiotix today announced organizational changes to align with strategic priorities post European market approval for Hensify (NBTXR3), which was cleared for marketing in April. 1 July 2019
Ever since Dr Scott Gottlieb unexpectedly stepped down as head of the US Food and Drug Administration in March this year, less than two years into his tenure, there has been speculation about where he would re-appear 28 June 2019
USA-based antibacterial products developer Entasis Therapeutics has announced the appointment of David Meek, currently chief executive of French pharma company Ipsen, as chairman of the board of directors, effective immediately. 25 June 2019
German drugmaker Stada Arzneimittel has nominated a successor for Enrique Häusermann, the long-time general manager of its Italian unit EG SpA. 20 June 2019
Valo Therapeutics, a cancer immunotherapy company developing neoantigen-coated oncolytic viruses as therapeutic vaccines, has appointed Dr Michael Stein to the full-time role of chief executive, having served as part-time co-chairman since inception in January 2017. 17 June 2019
Privately-held Akrevia Therapeutics today announced that Joseph Farmer has been appointed as chief operating officer of the biopharma company launched by Atlas Ventures and F-Prime last September. 13 June 2019
California-based rare diseases specialist Eiger BioPharmaceuticals today announced the appointment of Mark Mannebach, as vice president of global regulatory affairs. 10 June 2019
UK developer of inhaled therapeutics Vectura today announces that James Ward-Lilley will be stepping down from the Board and his position as chief executive on June 30, 2019. 10 June 2019
In a surprise announcement, French pharma major Sanofi has revealed that chief executive Olivier Brandicourt will retire in September, to be replaced by Novartis’ current pharma chief, Paul Hudson. 7 June 2019
Pfizer has announced that Jeff Settleman has joined the company as senior vice president and group head of Oncology Research and Development. 6 June 2019
After 20 years in various leadership roles with US pharma major Eli Lilly, Pete Salzmann has left to take the top job at a company specializing in autoimmune diseases. 6 June 2019
Bristol-Myers Squibb has outlined the executive team that will take the newly-enlarged firm forward after its acquisition of rival oncology specialist Celgene. 5 June 2019
California-based rare diseases specialist Eiger BioPharmaceuticals today announced the appointment of Jeysen Yogaratnam as vice president of global hepatitis Delta virus (HDV) clinical development. 5 June 2019
Privately-held Danish medical dermatology specialist LEO Pharma today announced that Gitte Aabo will step down as president and chief executive after 27 years in the company, 11 of which were as CEO. 4 June 2019
Germany’s Ethris, a leader in mRNA-based therapeutics, is expanding its leadership team by the addition of Thomas Langenickel in the role of chief medical officer. 4 June 2019
Jazz Pharmaceuticals today announced the appointment of Dr Robert Iannone as executive vice president, research and development, effective May 29, 2019. 3 June 2019